MAPT and Alzheimer disease: Given recent advancements in blood-based Alzheimer’s disease biomarkers, a single blood sample provides the ability to assess multiple aspects of the Alzheimer’s disease pathological processes, namely amyloid-β, tau and neurodegeneration.